Hyal2 (BC060047) Mouse Tagged ORF Clone Lentiviral Particle

CAT#: MR204921L4V

  • LentiORF®

Lenti ORF particles, Hyal2 (GFP-tagged) - Mouse hyaluronoglucosaminidase 2 (cDNA clone MGC:64716 IMAGE:5685601), 200ul, >10^7 TU/mL

ORF Plasmid: DDK tGFP



Need custom lentivirus service?
Get a free quote

CNY 11,115.00


货期*
详询

规格
    • 200 ul

Product images

经常一起买 (2)
Lenti ORF control particles of pLenti-C-mGFP-P2A-Puro, >1x10^7 TU/ml, 0.5 ml
    • 500 ul

CNY 2,950.00


One-Wash Lentivirus Titer Kit, HIV-1 p24 ELISA
    • 96 reactions

CNY 5,230.00

Specifications

Product Data
Product Name Hyal2 (BC060047) Mouse Tagged ORF Clone Lentiviral Particle
Synonyms AI256841; AU020858; AW555733
Vector pLenti-C-mGFP-P2A-Puro
ACCN BC060047
ORF Size 999 bp
Sequence Data
The ORF insert of this clone is exactly the same as(MR204921).
OTI Disclaimer The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
Reference Data
RefSeq BC060047
RefSeq Size 2996 bp
RefSeq ORF 1001 bp
Locus ID 15587
Gene Summary Hydrolyzes high molecular weight hyaluronic acid to produce an intermediate-sized product which is further hydrolyzed by sperm hyaluronidase to give small oligosaccharides. Displays very low levels of activity. Associates with and negatively regulates MST1R (By similarity).[UniProtKB/Swiss-Prot Function]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...